Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978638 | 0.93 | LMNA (0.59) | LMNAPOLBL3MBTL3L3MBTL1HSP90AB1 | |
| SCHEMBL4978686 | 0.89 | LMNA (0.64) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4979105 | 0.89 | HSP90AB1 (0.62) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4978720 | 0.89 | LMNA (0.53) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4977885 | 0.88 | LMNA (0.48) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4978651 | 0.86 | LMNA (0.51) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4976372 | 0.84 | LMNA (0.51) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4978255 | 0.83 | TRPV6 (0.53) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4980704 | 0.83 | LMNA (0.46) | LMNAPOLBHSP90AB1MAPTTP53 | |
| SCHEMBL4979825 | 0.82 | HSP90AB1 (0.73) | LMNAPOLBHSP90AB1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | LMNA 4534/4885POLB 1658/4885L3MBTL3 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.